Invest in 10,000+ US Stocks and ETFs
* Offering through VF Securities, Inc. (member FINRA/SIPC)
Profound Medical Corp., together with its subsidiaries, operates as a commercial-stage medical device company that develops and markets incision-free therapeutic systems for the image guided ablation of diseased tissue in Canada, Germany, the United States, and Finland. Its lead product TULSA-PRO system combines magnetic resonance imaging(MRI), robotically-driven transurethral sweeping action/thermal ultrasound and closed-loop temperature feedback control to provide precise, flexible, and durable ablation of a surgeon defined region of prostate and protect the urethra and rectum. The company also offers Sonalleve, which combines real-time MRI and thermometry for the treatment of uterine fibroids, adenomyotic tissue, palliative pain treatment of bone metastases, osteoid osteoma, and management of benign tumors. Profound Medical Corp. is headquartered in Mississauga, Canada. more
Time Frame | PROF | Sector | S&P500 |
---|---|---|---|
1-Week Return | -6.1% | -3.39% | 0.2% |
1-Month Return | -7.65% | -1.92% | 2.72% |
3-Month Return | -5.79% | -10.54% | 7.31% |
6-Month Return | -15.22% | -4.47% | 10.44% |
1-Year Return | -17.54% | 4.06% | 27.53% |
3-Year Return | -36.27% | 0.94% | 30.88% |
5-Year Return | -26.87% | 36.67% | 89.21% |
10-Year Return | -28.92% | 102.87% | 199.95% |
Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | 5YR TREND | |
---|---|---|---|---|---|---|
Total Revenue | 4.23M | 7.30M | 6.87M | 6.68M | 7.20M | [{"date":"2019-12-31","value":57.93,"profit":true},{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":94.1,"profit":true},{"date":"2022-12-31","value":91.47,"profit":true},{"date":"2023-12-31","value":98.56,"profit":true}] |
Cost of Revenue | 1.81M | 3.83M | 3.92M | 3.66M | 2.82M | [{"date":"2019-12-31","value":46.11,"profit":true},{"date":"2020-12-31","value":97.68,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":93.34,"profit":true},{"date":"2023-12-31","value":71.84,"profit":true}] |
Gross Profit | 2.42M | 3.47M | 2.95M | 3.02M | 4.38M | [{"date":"2019-12-31","value":55.31,"profit":true},{"date":"2020-12-31","value":79.28,"profit":true},{"date":"2021-12-31","value":67.37,"profit":true},{"date":"2022-12-31","value":68.94,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Gross Margin | 57.27% | 47.56% | 42.95% | 45.22% | 60.87% | [{"date":"2019-12-31","value":94.09,"profit":true},{"date":"2020-12-31","value":78.14,"profit":true},{"date":"2021-12-31","value":70.56,"profit":true},{"date":"2022-12-31","value":74.29,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Operating Expenses | 17.56M | 22.34M | 33.24M | 32.62M | 33.00M | [{"date":"2019-12-31","value":52.81,"profit":true},{"date":"2020-12-31","value":67.19,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":98.13,"profit":true},{"date":"2023-12-31","value":99.26,"profit":true}] |
Operating Income | (15.13M) | (18.86M) | (30.29M) | (29.60M) | (28.62M) | [{"date":"2019-12-31","value":-1513323968,"profit":false},{"date":"2020-12-31","value":-1886300000,"profit":false},{"date":"2021-12-31","value":-3029100000,"profit":false},{"date":"2022-12-31","value":-2960200000,"profit":false},{"date":"2023-12-31","value":-2861600000,"profit":false}] |
Total Non-Operating Income/Expense | (1.06M) | 2.57M | (613.00K) | 4.66M | 645.00K | [{"date":"2019-12-31","value":-22.84,"profit":false},{"date":"2020-12-31","value":55.19,"profit":true},{"date":"2021-12-31","value":-13.15,"profit":false},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":13.83,"profit":true}] |
Pre-Tax Income | (15.31M) | (21.58M) | (30.59M) | (28.38M) | (28.70M) | [{"date":"2019-12-31","value":-1530952713,"profit":false},{"date":"2020-12-31","value":-2157700000,"profit":false},{"date":"2021-12-31","value":-3059400000,"profit":false},{"date":"2022-12-31","value":-2838200000,"profit":false},{"date":"2023-12-31","value":-2869700000,"profit":false}] |
Income Taxes | 148.42K | 45.00K | 105.00K | 287.00K | (128.00K) | [{"date":"2019-12-31","value":51.71,"profit":true},{"date":"2020-12-31","value":15.68,"profit":true},{"date":"2021-12-31","value":36.59,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":-44.6,"profit":false}] |
Income After Taxes | (15.46M) | (21.62M) | (30.70M) | (28.67M) | (28.57M) | [{"date":"2019-12-31","value":-1545794513,"profit":false},{"date":"2020-12-31","value":-2162200000,"profit":false},{"date":"2021-12-31","value":-3069900000,"profit":false},{"date":"2022-12-31","value":-2866900000,"profit":false},{"date":"2023-12-31","value":-2856900000,"profit":false}] |
Income From Continuous Operations | (20.19M) | (21.62M) | (30.70M) | (28.67M) | (28.57M) | [{"date":"2019-12-31","value":-2019225000,"profit":false},{"date":"2020-12-31","value":-2162200000,"profit":false},{"date":"2021-12-31","value":-3069900000,"profit":false},{"date":"2022-12-31","value":-2866900000,"profit":false},{"date":"2023-12-31","value":-2856900000,"profit":false}] |
Income From Discontinued Operations | - | - | - | - | - | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Net Income | (15.46M) | (21.62M) | (30.70M) | (28.67M) | (28.57M) | [{"date":"2019-12-31","value":-1545794514,"profit":false},{"date":"2020-12-31","value":-2162200000,"profit":false},{"date":"2021-12-31","value":-3069900000,"profit":false},{"date":"2022-12-31","value":-2866900000,"profit":false},{"date":"2023-12-31","value":-2856900000,"profit":false}] |
EPS (Diluted) | (1.35) | (1.63) | (1.50) | (1.38) | (1.35) | [{"date":"2019-12-31","value":-135.1,"profit":false},{"date":"2020-12-31","value":-163,"profit":false},{"date":"2021-12-31","value":-150,"profit":false},{"date":"2022-12-31","value":-138,"profit":false},{"date":"2023-12-31","value":-135,"profit":false}] |
These ratios help you determine the liquidity of the company. Higher is better.
PROF | |
---|---|
Cash Ratio | 4.06 |
Current Ratio | 6.12 |
Quick Ratio | 5.16 |
These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.
PROF | |
---|---|
ROA (LTM) | -44.62% |
ROE (LTM) | -90.17% |
These ratios help you understand the company's liabilities, gauging the riskiness of the investment.
PROF | |
---|---|
Debt Ratio Lower is generally better. Negative is bad. | 0.26 |
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. | 0.74 |
These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.
PROF | |
---|---|
Trailing PE | NM |
Forward PE | NM |
P/S (TTM) | 24.20 |
P/B | 6.96 |
Price/FCF | NM |
EV/R | 21.71 |
EV/Ebitda | NM |
Profound Medical Corp (PROF) share price today is $7.235
Yes, Indians can buy shares of Profound Medical Corp (PROF) on Vested. To buy Profound Medical Corp from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in PROF stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.
Yes, you can purchase fractional shares of Profound Medical Corp (PROF) via the Vested app. You can start investing in Profound Medical Corp (PROF) with a minimum investment of $1.
You can invest in shares of Profound Medical Corp (PROF) via Vested in three simple steps:
The 52-week high price of Profound Medical Corp (PROF) is $11.42. The 52-week low price of Profound Medical Corp (PROF) is $6.88.
The price-to-earnings (P/E) ratio of Profound Medical Corp (PROF) is
The price-to-book (P/B) ratio of Profound Medical Corp (PROF) is 6.96
The dividend yield of Profound Medical Corp (PROF) is 0.00%
The market capitalization of Profound Medical Corp (PROF) is $217.41M
The stock symbol (or ticker) of Profound Medical Corp is PROF